The LinearTM 3-4 70 cm 8 Contact Lead Kit, part number M365SC2352700 is part of a spinal cord st...
FDA Device Recall #Z-2122-2020 — Class II — April 24, 2019
Recall Summary
| Recall Number | Z-2122-2020 |
| Classification | Class II — Moderate risk |
| Date Initiated | April 24, 2019 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Boston Scientific Neuromodulation Corporation |
| Location | Valencia, CA |
| Product Type | Devices |
| Quantity | 1 unit |
Product Description
The LinearTM 3-4 70 cm 8 Contact Lead Kit, part number M365SC2352700 is part of a spinal cord stimulation system for prescription use only as an aid in the management of chronic intractable pain of the trunk and/or limbs. Package Contents Percutaneous Permanent Lead Kits (1) Percutaneous Lead with pre-loaded Curved Stylet (1) Stylet Ring with a Curved and a Straight Stylet (4) Suture Sleeves (1) Insertion Needle with Stylet (1) Lead Blank (1) Steering Cap (1) OR Cable Assembly (2) Lead Position Labelsleft and right (non-sterile) (1) Device Registration Form/Temporary Patient Identification Card (1) Manual
Reason for Recall
The firm is initiating a voluntary removal of certain spinal cord stimulation leads, lead extensions, adapters, and deep brain stimulation lead extensions due to the "use by date" displayed on the label which is later than the correct "use by date". No adverse health consequence is expected to occur from this issue.
Distribution Pattern
Distributed OUS only. to 14 countries.
Lot / Code Information
Part number M365SC2352700; serial number 1042757.
Other Recalls from Boston Scientific Neuromodulation Cor...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2558-2025 | Class II | Vercise Deep Brain Stimulation Systems Surgical... | Jul 8, 2025 |
| Z-2340-2025 | Class II | Burr Hole Cover Kit, REF: M365DB4600C0; Burr H... | Jul 8, 2025 |
| Z-2485-2025 | Class II | Superion IDS Kit Superion Indirect Decompressi... | Jun 6, 2025 |
| Z-2617-2024 | Class II | WAVEWRITER ALPHA: Model: SC-1216, 16 IPG KIT, R... | Jul 17, 2024 |
| Z-1890-2024 | Class II | Vercise Genus Deep Brain Stimulation (DBS) Impl... | Apr 18, 2024 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.